Neuromuscular

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Neurology News Network for the week ending December 25, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

Two patients with late infantile GM1 gangliosidosis in Cohort 1 received a low dose of the treatment, reporting no serious adverse events. Passage Bio noted it plans to move forward with 2 additional cohorts.

The FDA has placed the investigational new drug application for the treatment on clinical hold.

The treatment was well-tolerated in children with AS, positively affecting constipation, a common symptom of the condition.

Here's what is coming soon to NeurologyLive®.

The phase 4 study will enroll 300 patients with amyotrophic lateral sclerosis who have started treatment with edaravone (Radicava; Mitsubishi Tanabe Pharma America).

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.

The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.

Kent Pryor, PhD, the CEO of ZZ Biotech, provided insight into a phase 2 trial that will evaluate the safety and efficacy of the investigational treatment in 16 patients with amyotrophic lateral sclerosis.

The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

Despite displaying safety, after accounting for baseline differences between groups, statistically significant clinical improvement was not observed in key secondary outcomes, exploratory clinical outcomes, or responder analyses.

The FDA has previously granted the Acadia Pharmaceuticals treatment fast track status and orphan drug designation for Rett syndrome.

Prespecified and post hoc analyses explored the heterogeneity of disease at baseline, with meaningful treatment effect indicated in a subset of patients with less severe ALS.